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Abstract
Heme oxygenase-1 (HO-1) system catabolizes heme 
into three products: carbon monoxide, biliverdin/biliru-
bin and free iron. It is involved in many physiological 
and pathophysiological processes. A great deal of data 
has demonstrated the roles of HO-1 in the formation, 
growth and metastasis of tumors. The interest in this 
system by investigators involved in gastrointestinal 
tumors is fairly recent, and few papers on HO-1 have 
touched upon this subject. This review focuses on the 
current understanding of the physiological signiﬁcance 
of HO-1 induction and its possible roles in the gastro-
intestinal tumors studied to date. The implications for 
possible therapeutic manipulation of HO-1 in gastroin-
testinal tumors are also discussed.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Heme oxygenase (HO) plays an important role in regu-
lating the intracellular heme level by cleaving heme 
into carbon monoxide (CO), biliverdin and free iron[1]. 
Three HO isoforms have been identiﬁed to date: HO-1, 
HO-2, and HO-3, among which the isoforms 1 and 2 
are the best known. HO-2 is constitutively and most 
highly expressed in neuronal tissues contributing to cell 
homeostasis, whereas HO-1, also referred to as heat 
shock protein-32 (Hsp32), is an inducible enzyme and 
relatively lowly expressed in most tissues[2]. HO-3, which 
is described in the rat brain, has no activity and is not 
expressed in humans[3].
HO-1 and HO-2 are different gene products. Unlike 
the constitutively expressed HO-2, HO-1 is exquisitely 
sensitive, not only to heavy metals[4], but to all kinds of  
stimuli and agents that cause oxidative stress and patho-
logical conditions, including ischemia[5], hemorrhagic 
shock[6], heat shock[7], hypoxia[8], UVA radiation[9], reac-
tive oxygen species (ROS)[10]. In fact, there is no other 
enzyme to date that is affected by so many stimuli of  
diverse nature as HO-1[2].
HO-1 is involved in many pathophysiological pro-
cesses, ranging from Alzheimer's disease to cancer. The 
interest in this system by investigators involved in gas-
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trointestinal tumors is fairly recent, and few reports on 
HO-1 have focused on this subject.
HO-DERIVANTS AND THEIR EFFECTS
All products of  HO activity are now suspected to be bi-
ologically active, in which metabolic pathway is involved 
in a wide variety of  physiological and pathophysiological 
processes[11]. Almost all CO produced in vivo comes from 
the degradation of  heme by HO. Depending on the cell 
type, CO can activate one or both key signaling pathways 
in numerous physiological and pathophysiological con-
ditions (Figure 1). One of  the pathways is soluble gua-
nylate cyclase (sGC)/cyclic guanosine monophosphate 
(cGMP), which has been implicated in mediating the 
effects of  CO on vascular contractility, the inhibition of  
smooth muscle proliferation, neurotransmission[12,13] and 
preventing apoptosis in endothelial cells[14] and fibro-
blasts[15]. Another one is p38 mitogen-activated protein 
kinase (MAPK) pathway, through which CO can medi-
ate the anti-inﬂammatory actions in a large measure[16-18]. 
Moreover, Chin et al[19] recently pointed out that CO has 
played an additional novel role as a host defense mol-
ecule agent against microbes (bactericidal agent).
HO-1 catalyzes the rate-limiting step in heme deg-
radation to biliverdin. Biliverdin is, in turn, converted 
into bilirubin by biliverdin reductase at the expense of  
NADPH. Biliverdin and bilirubin are potent antioxi-
dants[20,21]. Several studies have demonstrated that the 
administration of  biliverdin and/or bilirubin is potently 
cytoprotective in a variety of  pathophysiological events, 
including ischemia-reperfusion injury, transplant rejec-
tion and inflammatory bowel disease[22-25]. In addition, 
bilirubin is also known to modulate immune effector 
functions and suppress inﬂammatory response[26].
Fe2+, which is also a product of  heme degradation, 
upregulates an iron-transporter pump that removes intra-
cellular Fe2+ from the cell[27] and induces the expression of  
ferritin, a iron binding protein[28]. Expression of  ferritin 
is originally reported to protect endothelial cell against 
oxidant damage in vitro[28]. In addition, over-expression 
of  H-ferritin (heavy chain ferritin) has also been shown 
to protect cultured endothelial cells from undergoing 
apoptosis and protect livers from transplant-associated 
ischemia-reperfusion injury[29]. Although the roles of  
the iron and ferritin in the overall cytoprotective effect 
of  HO-1 are not clear, presumably both contribute in a 
crucial manner to the overall anti-oxidant effect following 
increased HO-1 expression in a variety of  situations[30].
EXPRESSION OF HO-1 IN 
GASTROINTESTINAL TUMORS
Expression of  HO-1 is usually increased in tumors, com-
pared with surrounding healthy tissues, which was shown 
in oral squamous cell carcinoma[31], pancreatic cancer[32] 
and hepatoma[33]. There have been few published reports 
in gastrointestinal tumors and only one paper to date has 
investigated HO-1 expression in gastrointestinal tumors. 
The study investigates the expression of  HO-1 in human 
colon tumor. Focal HO-1 expression in colorectal cancer 
and colonic adenoma was found to be 41.8% (23/55) and 
36.8% (7/19), respectively[34]. Of  importance, HO-1 in 
gastrointestinal tumors can be further upregulated in re-
sponse to chemotherapy[35] and photodynamic therapy[36].
HO-1 PROMOTER POLYMORPHISM
HO-1 is known as an oxidative stress responsive protein 
that is upregulated by multiple stimuli, which has been 
proposed to provide an important cellular response that 
protects cells against oxidative damage. However, humans 
differ quantitatively in their ability to mount an HO-1 
response. The association between the HO-1 genotype 
and various gastrointestinal tumors has been studied. Lo 
et al[37] examined the correlation between the HO-1 gene 
promoter polymorphism and the clinicopathological 
characteristics, along with the risk of  gastric cancer. Their 
ﬁndings suggest that the long (GT)n repeat of  HO-1 gene 
promoter was associated with a higher frequency of  gas-
tric adenocarcinoma, and the medium (GT)n repeat might 
possess a protective effect against gastric adenocarcinoma 
with a lower frequency of  lymphovascular invasion in tu-
mors. Additionally, the (GT)n-repeat promoter polymor-
phism was investigated in gastrointestinal stromal tumors 
(GIST) by Vashist et al[38]. They found that Short GTn 
allele (SGTn) was signiﬁcantly associated with metastasis, 
higher tumor recurrence rates and high-risk GIST. Fur-
thermore, SGTn allele carriers had significantly shorter 
disease-free and overall survival[38]. Moreover, a higher 
promoter activity genotype of  the HO-1 gene was associ-
ated with increased risk in women with gastric cancer[39]. 
In gastrointestinal tumors, a potential impact of  the (GT)n 
repeat polymorphism has been demonstrated, which 
might be considered as a potential prognostic marker to 
allocate patients to different risk groups and customize 
therapy and follow-up.
HO-1 AND CYTOPROTECTION AND 
APOPTOSIS
The gastrointestinal tract is lined by a simple epithelium 
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Figure 1  Schematic demonstration of mechanism underlying the 
biological actions of HO-1 pathway in tumors. HO-1: Heme oxygenase-1; 
CO: Carbon monoxide; sGC/cGMP: Soluble guanylate cyclase/cyclic guanosine 
monophosphate; MAPK: Mitogen-activated protein kinase.
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that undergoes constant renewal involving cell division, 
differentiation and cell death, in which HO-1 plays a 
major role in the regulation of  the cell cycle/apoptosis, 
oxidative stress, inﬂammation, development of  colon can-
cer[40]. Many studies have convincingly shown that HO-1 
is a cytoprotective and antiapoptotic enzyme in gastroin-
testinal tumor cells exposed to diverse stimuli (Figure 1). 
It has been demonstrated that HO-1 is involved in the 
pathogenesis of  human gastric cancer. Antiapoptotic ef-
fects of  HO-1 in gastric cancer cells are independent of  
p53 status in a p38 MAPK- and ERK-mediated pathway 
with elevated caspase inhibitory protein-2 (c-IAP2) and 
decreased caspase-3 activity[41], in which nuclear factor-κB 
is implicated. The pathway of  HO-1 was also investigated 
in HT29 human colon cancer cells by Park et al[42]. An-
other study also demonstrated that HO-1 induction re-
sulted in resistance to apoptosis in a human colon cancer 
cell line, Caco-2, whose effects were independent of  p38, 
but were mediated via Akt pathway[43]. In a similar study, 
Kim et al[44] reported that administration of  Zerumbone 
(ZER) effectively suppressed mouse colon carcinogenesis 
through multiple modulation of  growth, apoptosis and 
inflammation. Ohyama et al[45] examined the cytotoxicity 
of  a crude extract from Vitex agnus-castus fruits (Vitex 
extract) in gastric signet ring carcinoma (KATO-III) cells. 
They found that cell apoptosis may be attributed to the in-
hibition of  HO-1. It can be supposed that cytoprotective 
action of  HO-1 can be mediated by the following factors: 
(a) decreased intracellular pro-oxidant levels; (b) increased 
bilirubin levels; and (c) elevated CO production[46]. On the 
contrary, ﬂavonoids- (Vitex extract) induced apoptosis is 
caused through the induction of  HO-1 in human colon 
carcinoma cell line, COLO 201[35]. The relationship be-
tween HO-1 and apoptosis remains to be clariﬁed.
HO-1 AND TUMOR GROWTH AND 
METASTASIS
Apart from the cytoprotective action, HO-1 is com-
monly regarded as a potent proangiogenic enzyme. An-
giogenesis is critical not only for tumor growth but also 
for metastasis. Thus, proangiogenic action of  HO-1 may 
further support tumor progression[47]. Bussolati et al[48] 
reported that vascular endothelial growth factor (VEGF) 
induced prolonged HO-1 expression and activity in hu-
man endothelial cells and HO-1 inhibition abrogated 
VEGF-driven angiogenesis. Overexpression of  HO-1 in 
pancreatic cancer cells[49] and melanoma cells[50] increased 
the occurrence of  metastasis, while inhibition of  HO 
activity completely inhibited the occurrence of  metasta-
sis[49]. In contrast, some authors have demonstrated that 
inhibition of  the HO pathway by zinc deuteroporphyrin 
2,4-bis glycol (ZnDPBG) in colon carcinoma had no ef-
fect on metastasis to the lung and even increases metas-
tasis to the liver[51]. Furthermore, the rate of  lymphatic 
tumor invasion was signiﬁcantly lower in colorectal can-
cer samples expressing HO-1[34]. Thus, the mechanism 
of  HO-1 in the metastatic potential of  cancer cells is not 
recognized and it may depend on the type of  cancer or 
other still not deﬁned factors.
HO-1 AS A POTENTIAL THERAPEUTIC 
TARGET
Studies of  the role of  HO-1 seem to be important not 
only for better understanding of  tumor growth regula-
tion but also for clinical practice. HO-1 is often up-
regulated in gastrointestinal tumors[34], its expression is 
further increased in response to the different types of  
therapies such as photodynamic therapy[52,53] and pyrro-
lidine dithiocarbamate[54]. Since HO-1 may protect tumor 
cells against oxidative stress and can be regarded as an 
enzyme facilitating tumor progression, administration of  
HO-1 inhibitors might be effective for the treatment of  
gastrointestinal tumors. It has been demonstrated that 
pegylated zinc protoporphyrin, a potent HO inhibitor, 
administered in vitro induced apoptosis of  human colon 
carcinoma SW480 cells and inhibited growth of  murine 
colon carcinoma in vivo[55]. However, the growth, inva-
sion and metastasis of  tumors are a highly complex and 
multistep process, the mechanisms responsible for HO-1 
in gastrointestinal tumors remain to be elucidated.
CONCLUSION
HO-1 system may play an important role in different 
pathophysiological conditions, in which pharmacologic 
modulation of  HO-1 system may represent an effective 
and cooperative strategy to facilitate tumor growth and 
metastasis, although the exact effects can depend on the 
type of  disease. Therefore, down-regulating the HO-1 
system by pharmacological or genetic means will be a 
new therapeutic approach in the management of  gas-
trointestinal tumors. A comprehensive understanding of  
the underlying mechanisms for the observed effects of  
HO-1 and its products will be necessary before their use 
can be evaluated in clinical applications for the prevention 
and/or treatment of  human diseases such as gastrointesti-
nal tumors.
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